Cargando…
Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions
Zanubrutinib (BGB-3111, Brukinsa(®), BeiGene) is a next-generation irreversible inhibitor of Bruton’s tyrosine kinase (BTK), developed by BeiGene in 2012 for the treatment of B-cell malignancies. It was designed to minimize off-target inhibition of TEC- and EGFR-family kinases. Zanubrutinib is more...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076791/ https://www.ncbi.nlm.nih.gov/pubmed/37035197 http://dx.doi.org/10.3389/fonc.2023.1130595 |